Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK.
Allergy Department, 2nd Paediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.
Allergy. 2021 Jun;76(6):1765-1775. doi: 10.1111/all.14787. Epub 2021 Mar 24.
The interplay between COVID-19 pandemic and asthma in children is still unclear. We evaluated the impact of COVID-19 pandemic on childhood asthma outcomes.
The PeARL multinational cohort included 1,054 children with asthma and 505 non-asthmatic children aged between 4 and 18 years from 25 pediatric departments, from 15 countries globally. We compared the frequency of acute respiratory and febrile presentations during the first wave of the COVID-19 pandemic between groups and with data available from the previous year. In children with asthma, we also compared current and historical disease control.
During the pandemic, children with asthma experienced fewer upper respiratory tract infections, episodes of pyrexia, emergency visits, hospital admissions, asthma attacks, and hospitalizations due to asthma, in comparison with the preceding year. Sixty-six percent of asthmatic children had improved asthma control while in 33% the improvement exceeded the minimal clinically important difference. Pre-bronchodilatation FEV and peak expiratory flow rate were improved during the pandemic. When compared to non-asthmatic controls, children with asthma were not at increased risk of LRTIs, episodes of pyrexia, emergency visits, or hospitalizations during the pandemic. However, an increased risk of URTIs emerged.
Childhood asthma outcomes, including control, were improved during the first wave of the COVID-19 pandemic, probably because of reduced exposure to asthma triggers and increased treatment adherence. The decreased frequency of acute episodes does not support the notion that childhood asthma may be a risk factor for COVID-19. Furthermore, the potential for improving childhood asthma outcomes through environmental control becomes apparent.
COVID-19 大流行和儿童哮喘之间的相互作用仍不清楚。我们评估了 COVID-19 大流行对儿童哮喘结局的影响。
PeARL 多国队列纳入了来自全球 15 个国家的 25 个儿科部门的 1,054 例哮喘儿童和 505 例非哮喘儿童,年龄在 4 至 18 岁之间。我们比较了两组在 COVID-19 大流行第一波期间急性呼吸道和发热发作的频率,并与前一年的数据进行了比较。在哮喘儿童中,我们还比较了当前和历史疾病控制情况。
与前一年相比,在大流行期间,哮喘儿童经历的上呼吸道感染、发热发作、急诊就诊、住院、哮喘发作和因哮喘住院的次数更少。66%的哮喘儿童哮喘控制得到改善,其中 33%的改善超过了最小临床重要差异。在大流行期间,预支气管扩张 FEV 和呼气峰流速得到改善。与非哮喘对照组相比,哮喘儿童在大流行期间没有增加发生下呼吸道感染、发热发作、急诊就诊或住院的风险。然而,上呼吸道感染的风险增加了。
在 COVID-19 大流行的第一波期间,儿童哮喘结局,包括控制情况,得到了改善,这可能是因为接触哮喘诱因减少和治疗依从性提高。急性发作频率的降低不支持儿童哮喘可能是 COVID-19 的危险因素的观点。此外,通过环境控制改善儿童哮喘结局的潜力变得明显。